News: Clinical Trials

Brian Rini, MD, an internationally recognized leader in genitourinary oncology, kidney cancer, and clinical drug development, is joining Vanderbilt-Ingram Cancer Center as the inaugural chief of Clinical Trials.

A new multisite study will examine whether co-occurring Alzheimer’s disease and stage 4 breast or prostate cancer alters pain perception, potentially leading to undertreated cancer pain.

A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.

Vanderbilt University Medical Center is the nation’s leading recruitment site for a new study examining the effectiveness of donor nerve grafts to restore sensation to breast tissue following mastectomy and reconstruction.

Vanderbilt University Medical Center is participating in an international study to determine the effectiveness of a new therapeutic vaccine for treating women with precancerous changes on the cervix.

Patients who received atezolizumab in addition to standard chemotherapy lived two months longer than those treated with chemotherapy alone, according to a recent study published in the New England Journal of Medicine.

Vanderbilt investigators have conducted a prospective multicenter study on how extracorporeal photopheresis works in treating chronic graft-versus-host disease (cGVHD) — a complication of bone marrow or stem cell transplant that occurs when donor cells attack the recipient.

Jordan Berlin, MD, has been named associate director of Clinical Investigation Strategy and Shared Resources at Vanderbilt-Ingram Cancer Center (VICC). In his new role he will chair the Resource Allocation Committee and continue as chair of the Clinical Trials Shared Resource (CTSR) Steering Committee.

My Cancer Genome (MCG), a web-based cancer information tool developed by Vanderbilt-Ingram Cancer Center investigators in 2011 and supported by GenomOncology, has launched a new clinical trial search tool that allows website visitors to search for cancer clinical trials based on disease, biomarker, phase and recruiting status.

Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.